Chronic Lymphocytic Leukemia:
Age Requirement: >= 18
Duration: 12 Month(s)
Specialist Required: Yes
Documented Diagnosis: Yes
Medical Test Required: No
Specialist Type(s): 1 of Hematologist;Oncologist
Reauthorization Required: Yes
Duration of Reauthorization: = 1 plan year
Drug Policy Based On: 1 of FDA Approved Indications;NCCN Guidelines
Supporting Documentation Requirements: 1 of Chart Notes;Lab Tests
Concomitant Therapy Requirement: obinutuzumab
Diagnosis Types: 2 of as a single agent;Chronic Lymphocytic Leukemia;CLL for relapsed/refractory disease;patients with CLL who have received at least one prior therapy;Small Lymphocytic Lymphoma